pre-IPO PHARMA

chondrial-therapeutics PRESS RELEASE ARCHIVE

May 29, 2020

Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics


Dec 18, 2019

Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia


Dec 18, 2019

Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement


Feb 6, 2017

Chondrial Therapeutics Secures Up to $22.6 Million in Series A Financing and Licenses Novel Technology for the Treatment of Friedreich's Ataxia


Google Analytics Alternative